A Single-blind, Placebo-controlled, Dose-ranging Trial of Oral Hepatic-directed Vesicle Insulin Add-on to Oral Antidiabetic Treatment in Patients With Type 2 Diabetes Mellitus

Background: The dose response of postprandial plasma glucose (PPG) to add-on, premeal oral hepatic-directed vesicle-insulin (HDV-I), an investigational lipid bio-nanoparticle hepatocyte-targeted insulin delivery system, was evaluated in a 3-test-meal/day model in type 2 diabetes patients. Method: Th...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Journal of diabetes science and technology 2014-05, Vol.8 (3), p.551-559
Hauptverfasser:	Geho, W. Blair, Rosenberg, Len N., Schwartz, Sherwyn L., Lau, John R., Gana, Theophilus J.
Format:	Artikel
Sprache:	eng
Schlagworte:	Administration, Oral Area Under Curve Biomarkers - blood Blood Glucose - drug effects Blood Glucose - metabolism Capsules Diabetes Mellitus, Type 2 - blood Diabetes Mellitus, Type 2 - diagnosis Diabetes Mellitus, Type 2 - drug therapy Drug Therapy, Combination Female Glycated Hemoglobin A - metabolism Humans Hypoglycemic Agents - administration & dosage Hypoglycemic Agents - adverse effects Insulin - administration & dosage Insulin - adverse effects Insulin - analogs & derivatives Male Middle Aged Nanoparticles - administration & dosage Nanoparticles - adverse effects Original Single-Blind Method Texas Time Factors Treatment Outcome
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!